Silk Road Medical, Inc (NASDAQ:SILK) CEO Sells $849,825.30 in Stock

Silk Road Medical, Inc (NASDAQ:SILKGet Rating) CEO Erica J. Rogers sold 18,043 shares of the stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $47.10, for a total value of $849,825.30. Following the completion of the transaction, the chief executive officer now owns 269,132 shares in the company, valued at $12,676,117.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Silk Road Medical Trading Up 1.3 %

Shares of SILK stock opened at $47.89 on Tuesday. The firm has a 50 day moving average price of $52.47 and a two-hundred day moving average price of $48.59. The company has a quick ratio of 9.62, a current ratio of 10.41 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $1.84 billion, a PE ratio of -30.90 and a beta of 1.22. Silk Road Medical, Inc has a 12-month low of $27.30 and a 12-month high of $58.04.

Silk Road Medical (NASDAQ:SILKGet Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Silk Road Medical had a negative net margin of 39.81% and a negative return on equity of 63.30%. The company had revenue of $40.07 million during the quarter, compared to the consensus estimate of $37.35 million. During the same period in the previous year, the business earned ($0.42) earnings per share. The firm’s quarterly revenue was up 41.8% on a year-over-year basis. As a group, analysts predict that Silk Road Medical, Inc will post -1.51 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on SILK. Argus increased their price objective on Silk Road Medical from $60.00 to $70.00 in a research report on Monday, January 9th. Bank of America initiated coverage on Silk Road Medical in a research note on Tuesday, November 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Wolfe Research downgraded Silk Road Medical from an “outperform” rating to a “peer perform” rating in a research note on Tuesday, February 7th. Finally, Citigroup increased their price target on Silk Road Medical to $38.00 in a research note on Tuesday, November 15th.

Institutional Trading of Silk Road Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. grew its stake in shares of Silk Road Medical by 91.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 466 shares of the company’s stock worth $25,000 after purchasing an additional 222 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Silk Road Medical during the third quarter valued at $30,000. MCF Advisors LLC bought a new stake in Silk Road Medical during the third quarter valued at $43,000. Nisa Investment Advisors LLC bought a new stake in Silk Road Medical during the second quarter valued at $38,000. Finally, US Bancorp DE boosted its position in Silk Road Medical by 41.3% during the first quarter. US Bancorp DE now owns 1,673 shares of the company’s stock valued at $69,000 after acquiring an additional 489 shares during the last quarter. Institutional investors own 96.43% of the company’s stock.

About Silk Road Medical

(Get Rating)

Silk Road Medical, Inc develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Featured Stories

Insider Buying and Selling by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.